Pheniramine Maleate (Avil)

Pheniramine Maleate (Avil)

Pheniramine Maleate, commonly marketed under the brand name Avil, is a first-generation antihistamine widely used to treat allergic reactions. As a potent H1 receptor antagonist, Pheniramine Maleate works by blocking histamine activity, alleviating symptoms such as sneezing, runny nose, itching, and skin rashes. Due to its mild sedative effect, it is also employed in cases of motion sickness and insomnia.




Uses of Pheniramine Maleate

Pheniramine Maleate is extensively used for various allergic conditions and other medical purposes, including:

  • Treatment of seasonal allergic rhinitis (hay fever)
  • Relief from urticaria (hives) and eczema
  • Management of insect bites and stings
  • Adjunct therapy for anaphylaxis alongside epinephrine
  • Treatment of drug and food allergies
  • Motion sickness and nausea
  • Sedative purposes in minor cases of insomnia
  • Used in combination with other medications for cold and flu relief

Dosage and Administration

Pheniramine Maleate dosage varies based on age, condition, and severity.

General Dosage Guidelines:

  • Adults: 25–50 mg orally, up to three times daily
  • Children (5-10 years): 10–15 mg, up to three times daily
  • Children (above 10 years): 15–30 mg, up to three times daily
  • Elderly Patients: Dose should be adjusted due to increased susceptibility to sedation and dizziness

Pheniramine Maleate is available in various forms such as tablets, syrups, and injectables. It should be taken with or without food but is best avoided with alcohol due to its sedative effects.




Dose Adjustment in Different Diseases

  • Hepatic Impairment: Requires dose reduction due to potential liver metabolism issues.
  • Renal Impairment: Adjustments needed for those with moderate to severe kidney dysfunction to prevent toxicity.
  • Cardiovascular Disease: Used with caution due to potential arrhythmia risk.
  • Pregnancy and Lactation: Should be avoided unless prescribed by a physician.

Drug Combinations in Use

Pheniramine Maleate is often combined with other drugs to enhance therapeutic effects:

Combination Drug

Purpose

Paracetamol

Used in cold and flu medications for fever and pain relief

Caffeine

Helps counteract sedation caused by Pheniramine Maleate

Phenylephrine

Used in decongestants to relieve nasal congestion

Codeine

Found in cough syrups for suppressing severe cough


Presentation or Form

Pheniramine Maleate is available in the following forms:

  • Tablets (25 mg, 50 mg) – Used for oral administration
  • Syrup (2 mg/ml) – For pediatric and geriatric patients
  • Injectable solution (45.5 mg/ml) – Used in emergency allergic reactions

Pharmacokinetics of Pheniramine Maleate

  • Absorption: Rapidly absorbed from the gastrointestinal tract
  • Onset of Action: 30 minutes post-administration
  • Peak Plasma Concentration: Achieved within 1–3 hours
  • Metabolism: Primarily hepatic metabolism
  • Excretion: Eliminated via the kidneys with a half-life of approximately 16–19 hours

Pharmacodynamics of Pheniramine Maleate

Pheniramine Maleate exerts its effects by blocking H1 histamine receptors, preventing histamine-induced symptoms such as itching, swelling, and vasodilation. It also has mild anticholinergic and sedative properties, contributing to drowsiness and dry mouth.



Drug Interactions

Pheniramine Maleate interacts with several drugs, leading to enhanced or diminished effects:

  • Central Nervous System Depressants (e.g., alcohol, benzodiazepines): Increased sedation
  • Monoamine Oxidase Inhibitors (MAOIs): Potentiated antihistaminic effects
  • Anticholinergic Drugs: Increased risk of dry mouth, constipation, and urinary retention
  • Beta-Blockers: May exacerbate hypotension

Comparison with Other Drugs of the Same Category

Drug Name

Sedation Level

Duration of Action

Uses

Pheniramine Maleate

Moderate

16-19 hours

Allergies, motion sickness, insomnia

Diphenhydramine

High

4-8 hours

Insomnia, severe allergies

Loratadine

Low

24 hours

Seasonal allergies

Cetirizine

Low

24 hours

Allergies, urticaria

Precautions and Special Considerations

  • Should not be used while operating heavy machinery or driving due to drowsiness
  • Not recommended in patients with severe hypertension or arrhythmias
  • Avoid alcohol consumption to prevent excessive sedation
  • Should be used cautiously in asthmatic patients as it may thicken bronchial secretions

Toxicity and Overdose

Overdose symptoms of Pheniramine Maleate include:

  • Extreme drowsiness
  • Confusion and agitation
  • Hallucinations
  • Seizures
  • Respiratory depression

Antidote

In case of an overdose, symptomatic and supportive treatment is recommended. Gastric lavage, activated charcoal administration, and IV fluids may be necessary. Severe cases may require mechanical ventilation.

Effects of Pheniramine Maleate

  • Positive Effects: Effective relief from allergies, itching, and inflammation
  • Negative Effects: Drowsiness, dizziness, dry mouth, nausea, blurred vision
  • Long-Term Effects: Prolonged use can lead to tolerance, dependency, and cognitive impairment in elderly patients

Recent Updates (2025) and Guidelines

  • 2025 Guidelines: Recent studies suggest Pheniramine Maleate should be used cautiously in the elderly due to increased fall risk.
  • New Formulations: Research is exploring a controlled-release version to reduce drowsiness while maintaining efficacy.
  • Regulatory Updates: Certain countries are considering restricting over-the-counter availability due to misuse.

Facts to Remember

  • Pheniramine Maleate is a first-generation antihistamine.
  • It has sedative properties unlike second-generation antihistamines.
  • It is often used in cold and flu medications.
  • Available in tablet, syrup, and injectable forms.
  • Overdose can cause serious CNS depression and cardiac toxicity.

References

  1. British National Formulary (BNF) 2025
  2. World Health Organization (WHO) Allergy Treatment Guidelines
  3. National Institute for Health and Care Excellence (NICE) Guidelines
  4. European Medicines Agency (EMA) Drug Safety Report
  5. Recent Clinical Trials on Antihistamines – PubMed Database (2025)


No comments:

Post a Comment